Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2017
At a glance
- Drugs Dabrafenib (Primary) ; Iodine radioactive
- Indications Thyroid cancer
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 17 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Aug 2012 Actual initiation date (1 Jul 2012) added as reported by ClinicalTrials.gov.